°£¾Ï Ä¡·áÁ¦ ½ÃÀå : ¾àÁ¦ Ŭ·¡½ºº°, Ä¡·á À¯Çüº°, Åõ¿© °æ·Îº°, ÃÖÁ¾»ç¿ëÀÚº°, ±¹°¡º°, Áö¿ªº° - »ê¾÷ ºÐ¼®, ½ÃÀå ±Ô¸ð, ½ÃÀå Á¡À¯À², ¿¹Ãø(2024-2032³â)
Liver Cancer Drug Market, By Drug Class, By Therapy Type, By Route of Administration, By End-User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
»óǰÄÚµå : 1584133
¸®¼­Ä¡»ç : AnalystView Market Insights
¹ßÇàÀÏ : 2024³â 11¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 260 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,250 £Ü 4,702,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç, ÅØ½ºÆ®ÀÇ Copy&Pasteµµ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 4,650 £Ü 6,728,000
PDF (5 User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,650 £Ü 8,174,000
PDF & Excel (Enterprise User License) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ³» ¸ðµç »ç¿ëÀÚ°¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy&Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¸®Æ÷Æ® ÇÏÀ̶óÀÌÆ®

°£¾Ï Ä¡·áÁ¦ ½ÃÀå ±Ô¸ð´Â 2023³â¿¡ 31¾ï 5,190¸¸ ´Þ·¯¿¡ ´ÞÇϸç, 2024-2032³â 17.82%ÀÇ CAGR·Î È®´ë

°£¾Ï Ä¡·áÁ¦ ½ÃÀå - ½ÃÀå ¿ªÇÐ

°£¾Ï ÀÌȯÀ²ÀÇ »ó½ÂÀÌ °£¾Ï Ä¡·áÁ¦ ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁø

¼¼°èº¸°Ç±â±¸(WHO)ÀÇ º¸°í¿¡ µû¸£¸é Áö³­ 20³â°£ °£¾Ï ¹ßº´·üÀÌ 75% ÀÌ»ó Áõ°¡Çß´Ù°í ÇÕ´Ï´Ù. ¹Ì±¹ ¾Ï Çùȸ´Â 2023³â±îÁö ¹Ì±¹¿¡¼­¸¸ ¾à 43,000¸íÀÇ °£¾Ï ȯÀÚ°¡ »õ·Î Áø´ÜµÉ °ÍÀ¸·Î ÃßÁ¤Çϰí ÀÖÀ¸¸ç, ÀÌ´Â ÁÖ·Î BÇü ¹× CÇü °£¿° °¨¿°·ü Áõ°¡, °úµµÇÑ ¾ËÄÚ¿Ã ¼·Ãë, ºñ¸¸ µîÀÌ ¿øÀÎÀ¸·Î ²ÅÈü´Ï´Ù. Á¶±â ¹ß°ß°ú Á¶±â Ä¡·áÀÇ Á߿伺¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó Á¦¾à»çµéÀº Çõ½ÅÀûÀÎ Ä¡·á¹ýÀ» °³¹ßÇÏ¸ç ´ëÀÀÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î ¸é¿ª°ü¹®¾ïÁ¦Á¦¿Í °°Àº Ç¥Àû Ä¡·áÁ¦ÀÇ ÃÖ±Ù ¹ßÀüÀº ÁøÇ༺ °£¾Ï ȯÀÚÀÇ »ýÁ¸À²À» °³¼±ÇÏ´Â µ¥ À¯¸ÁÇÑ °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù. ¶ÇÇÑ ¹Ì±¹ °£ÇÐȸ¿Í °°Àº Á¶Á÷Àº Ä¡·á ¿É¼ÇÀ» ´Ã¸®°í ÀÌ Áúº´À» ´õ Àß ÀÌÇØÇϱâ À§ÇÑ ¿¬±¸¿Í ÀÓ»ó½ÃÇèÀ» ÃßÁøÇÏ¿© ºü¸£°Ô ¹ßÀüÇÏ´Â ÀÌ ½ÃÀå¿¡¼­ È¿°úÀûÀÎ Ä¡·á¹ý¿¡ ´ëÇÑ ±ä±ÞÇÑ Çʿ伺¿¡ ´ëÀÀÇϰí ÀÖ½À´Ï´Ù.

°£¾Ï Ä¡·áÁ¦ ½ÃÀå - ÁÖ¿ä ÀλçÀÌÆ®

´ç»çÀÇ ¸®¼­Ä¡ ¾Ö³Î¸®½ºÆ®ÀÇ ºÐ¼®¿¡ µû¸£¸é ¼¼°è ½ÃÀåÀº ¿¹Ãø ±â°£(2024-2032) µ¿¾È ¿¬Æò±Õ ¾à 17.82%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î ¸Å³â ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¾à¹° À¯Çüº°·Î´Â VEGF ¾ïÁ¦Á¦°¡ 22023³â °¡Àå ³ôÀº ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

Ä¡·á À¯Çüº°·Î´Â 2023³â Ç¥ÀûÄ¡·áÁ¦°¡ ÁÖ¿ä Ä¡·á À¯ÇüÀ¸·Î ºÎ»óÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Åõ¿© °æ·Îº°·Î´Â °æ±¸Á¦°¡ 2023³â ÁÖ¿ä À¯ÇüÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù.

Áö¿ªº°·Î´Â ºÏ¹Ì°¡ 2023³â ¸ÅÃâÀ» ÁÖµµÇß½À´Ï´Ù.

°£¾Ï Ä¡·áÁ¦ ½ÃÀå - ¼¼ºÐÈ­ ºÐ¼® :

°£¾Ï Ä¡·áÁ¦ ¼¼°è ½ÃÀåÀº ¾à¹° À¯Çüº°, Ä¡·á À¯Çüº°, Åõ¿© °æ·Îº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº° ½ÃÀåÀ¸·Î ±¸ºÐµË´Ï´Ù.

¾à¹° À¯Çü¿¡ µû¶ó VEGF ¾ïÁ¦Á¦, PD-1/PD-L1 ¾ïÁ¦Á¦, Ƽ·Î½Å Ű³ª¾ÆÁ¦ ¾ïÁ¦Á¦, ¸é¿ª°ü¹®¾ïÁ¦Á¦ µî 4°¡Áö·Î ºÐ·ùµÇ¸ç, VEGF ¾ïÁ¦Á¦´Â °£¼¼Æ÷¾Ï¿¡ ´ëÇÑ È¿´ÉÀÌ ÀÔÁõµÇ¾î °£¾Ï Ä¡·áÁ¦ ½ÃÀå¿¡¼­ °¡Àå ³ôÀº ¼øÀ§¸¦ Â÷ÁöÇϰí ÀÖÀ¸¸ç, PD-1/PD- L1 ¾ïÁ¦Á¦°¡ ±× µÚ¸¦ À̾î À¯¸ÁÇÑ ¸é¿ªÄ¡·á ¿É¼ÇÀ» Á¦°øÇÕ´Ï´Ù. ±× ´ÙÀ½À¸·Î´Â Ƽ·Î½Å Ű³ª¾ÆÁ¦ ¾ïÁ¦Á¦(TKI), ¸é¿ª°ü¹®¾ïÁ¦Á¦°¡ ÁøÇ༺ ȯÀÚ¿¡¼­ ¼±È£µÇ°í ÀÖ½À´Ï´Ù.

½ÃÀåÀº Ä¡·á¹ý À¯Çü¿¡ µû¶ó È­Çпä¹ý, Ç¥ÀûÄ¡·áÁ¦, ¸é¿ª¿ä¹ý, º´¿ë¿ä¹ý µî 4°¡Áö ¹üÁÖ·Î ³ª´¹´Ï´Ù. Ç¥ÀûÄ¡·áÁ¦´Â ³ôÀº Ä¡·á È¿°ú¿Í Á¤È®¼ºÀ¸·Î °£¾Ï Ä¡·áÁ¦ ½ÃÀåÀ» ¼±µµÇϰí ÀÖ½À´Ï´Ù. ¸é¿ª¿ä¹ýÀº ÁøÇ༺ °£¾Ï¿¡ ´ëÇÑ Çõ½ÅÀûÀÎ Ä¡·á ¿É¼ÇÀ» Á¦°øÇÏ¸ç ±Ù¼ÒÇÑ Â÷ÀÌ·Î ±× µÚ¸¦ À̾ú½À´Ï´Ù. ±× ´ÙÀ½À¸·Î´Â º´¿ë¿ä¹ýÀÌ µÚ¸¦ À̾úÁö¸¸, È­Çпä¹ýÀº ¿©ÀüÈ÷ ÀüÅëÀûÀÎ Á¢±Ù¹ýÀ¸·Î ÁøÇ༺ °£¾Ï¿¡ ´ëÇÑ È¿°ú°¡ Á¦ÇÑÀûÀ̶ó´Â Æò°¡¸¦ ¹Þ°í ÀÖ½À´Ï´Ù.

°£¾Ï Ä¡·áÁ¦ ½ÃÀå - Áö¿ªÀû ÀλçÀÌÆ®

ºÏ¹Ì°¡ °£¾Ï Ä¡·áÁ¦ ½ÃÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ƯÈ÷ ¹Ì±¹ ½ÄǰÀǾ౹(FDA)Àº 2022³â ·»¹ÙƼ´Õ°ú Æèºê·Ñ¸®ÁÖ¸¿À» Æ÷ÇÔÇÑ »õ·Î¿î º´¿ë¿ä¹ýÀ» ½ÂÀÎÇÏ¿© ÁøÇ༺ °£¼¼Æ÷¾Ï(HCC) ȯÀÚÀÇ Ä¡·á ¿É¼ÇÀ» Å©°Ô Çâ»ó½ÃÄ×À¸¸ç, °£¾Ï ¹ßº´·üÀÌ ²ÙÁØÈ÷ Áõ°¡Çϰí ÀÖ´Ù°í º¸°íÇß½À´Ï´Ù. ¶ÇÇÑ ¹Ì±¹ ¾ÏÇÐȸ´Â °£¾Ï ¹ßº´·üÀÌ ²ÙÁØÈ÷ Áõ°¡Çϰí ÀÖ´Ù°í º¸°íÇϰí, ´õ ³ªÀº Áø´Ü Åø¿Í Ä¡·á ¿É¼ÇÀ» À§ÇÑ ¿¬±¸ ±¸»ó¿¡ ´ëÇÑ ÀÚ±Ý Áö¿øÀ» ´Ã·È½À´Ï´Ù. À¯·´¿¡¼­´Â µ¶Àϰú ÇÁ¶û½º¿Í °°Àº ±¹°¡¿¡¼­ Çõ½ÅÀûÀÎ ¾à¹° Á¶ÇÕ¿¡ ÃÊÁ¡À» ¸ÂÃá ÀÓ»ó½ÃÇèÀÌ ±ÞÁõÇϰí ÀÖÀ¸¸ç, À̴ ȯÀÚ Ä¡·á °­È­¿¡ ´ëÇÑ ³ë·ÂÀ» ¹Ý¿µÇϰí ÀÖ½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀº °£¿°°ú °ü·ÃµÈ °£¾ÏÀÇ ³ôÀº À¯º´·ü·Î ÀÎÇØ °£¾Ï ¿¬±¸¿¡ ¸¹Àº ÅõÀÚ°¡ ÀÌ·ç¾îÁö°í ÀÖÀ¸¸ç, Áß¿äÇÑ Áö¿ªÀ¸·Î ºÎ»óÇϰí ÀÖ½À´Ï´Ù. ÀϺ»ÀÇ Á¦¾àȸ»ç¿Í ¿¬±¸±â°üÀÇ Á¦ÈÞ¿Í °°Àº °øµ¿¿¬±¸´Â »õ·Î¿î Ä¡·á¹ý °³¹ßÀ» ÃËÁøÇÏ´Â °ÍÀ» ¸ñÇ¥·Î Çϰí ÀÖÀ¸¸ç, °£¾Ï°ú È¿°úÀûÀ¸·Î ½Î¿ì±â À§ÇÑ Àü ¼¼°èÀÇ ³ë·ÂÀ» °­Á¶Çϰí ÀÖ½À´Ï´Ù.

°£¾Ï Ä¡·áÁ¦ ½ÃÀå - °æÀï»óȲ:

°£¾Ï Ä¡·áÁ¦ ½ÃÀå °æÀï ±¸µµ´Â ÁÖ·Î ºÏ¹Ì°¡ ÁÖµµÇϰí ÀÖÀ¸¸ç, ¹ÙÀÌ¿¤, ºê¸®½ºÅç-¸¶À̾ ½ºÄûºê, ¸ÓÅ© µî ÁÖ¿ä Á¦¾à»çµéÀÌ Àû±ØÀûÀ¸·Î Æ÷Æ®Æú¸®¿À¸¦ È®ÀåÇϰí ÀÖ½À´Ï´Ù. Ä¡·á ¼ºÀû °³¼±À» ¸ñÇ¥·Î ÇÏ´Â »õ·Î¿î ¼Ö¶óÆä´Õ Á¦Á¦¸¦ Ãâ½ÃÇÒ ¿¹Á¤À̶ó°í ¹ßÇ¥Çß½À´Ï´Ù. ÇÑÆí, ºê¸®½ºÅç ¸¶À̾ ½ºÄûºê´Â ¹Ì±¹ ±¹¸³¾Ï¿¬±¸¼Ò¿ÍÀÇ °øµ¿¿¬±¸¸¦ ÅëÇØ »õ·Î¿î ¸é¿ª¿ä¹ý °³¹ßÀ» °¡¼ÓÈ­ÇÏ¿© ȯÀÚµéÀÇ Ä¡·á ¿É¼ÇÀ» Å©°Ô È®´ëÇß½À´Ï´Ù. ÃÖ±Ù ¸ÓÅ©´Â °£¾Ï ¿¬±¸ Àü¹® »ý¸í°øÇÐ ±â¾÷À» ÀμöÇÏ¿© ½ÃÀå ÀÔÁö¸¦ °­È­Çϰí Çõ½ÅÀûÀÎ Ä¡·á¹ý ÆÄÀÌÇÁ¶óÀÎÀ» È®ÀåÇß½À´Ï´Ù. ¶ÇÇÑ À¯·´ ½ÃÀå¿¡¼­´Â ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁü¿¡ µû¶ó ±âÁ¸ ¾à¹°°ú ½Å¾àÀ» °áÇÕÇÑ º´¿ë¿ä¹ý ÀÓ»ó½ÃÇèÀÌ È°¹ßÈ÷ ÁøÇàµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿òÁ÷ÀÓÀº °£¾Ï Ä¡·á ¿É¼ÇÀ» ³ÐÈ÷°í ȯÀÚÀÇ ¿¹Èĸ¦ °³¼±Çϱâ À§Çؼ­´Â °øµ¿ ¿¬±¸, Çõ½Å, Àü·«Àû Á¦ÈÞ°¡ ÇʼöÀûÀ̶ó´Â ¿ªµ¿ÀûÀÎ °æÀï ȯ°æÀ» °­Á¶Çϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå °£¾Ï Ä¡·áÁ¦ ½ÃÀå °³¿ä

Á¦2Àå °³¿ä

Á¦3Àå °£¾Ï Ä¡·áÁ¦ÀÇ ÁÖ¿ä ½ÃÀå µ¿Çâ

Á¦4Àå °£¾Ï Ä¡·áÁ¦ ¾÷°èÀÇ ¿¬±¸

Á¦5Àå °£¾Ï Ä¡·áÁ¦ ½ÃÀå : COVID-19ÀÇ ¿µÇ⠺м®

Á¦6Àå °£¾Ï Ä¡·áÁ¦ ½ÃÀå ±¸µµ

Á¦7Àå °£¾Ï Ä¡·áÁ¦ ½ÃÀå - ¾àÁ¦ Ŭ·¡½ºº°

Á¦8Àå °£¾Ï Ä¡·áÁ¦ ½ÃÀå - Ä¡·á À¯Çüº°

Á¦9Àå °£¾Ï Ä¡·áÁ¦ ½ÃÀå - Åõ¿© °æ·Îº°

Á¦10Àå °£¾Ï Ä¡·áÁ¦ ½ÃÀå - ÃÖÁ¾»ç¿ëÀÚº°

Á¦11Àå °£¾Ï Ä¡·áÁ¦ ½ÃÀå - Áö¿ªº°

Á¦12Àå ÁÖ¿ä º¥´õ ºÐ¼® - °£¾Ï Ä¡·áÁ¦ ¾÷°è

Á¦13Àå ¾Ö³Î¸®½ºÆ®ÀÇ Àü¹æÀ§ Àü¸Á

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

REPORT HIGHLIGHT

Liver Cancer Drug Market size was valued at USD 3,151.90 Million in 2023, expanding at a CAGR of 17.82% from 2024 to 2032.

The Liver Cancer Drug Market focuses on pharmaceutical treatments for hepatocellular carcinoma (HCC), the most common type of liver cancer, accounting for approximately 75% of all liver cancer cases. Rising incidences of liver cancer, attributed to factors like hepatitis infection and alcohol consumption, have heightened the demand for effective therapies. For instance, the World Health Organization estimates that liver cancer caused around 830,000 deaths globally in 2020. The advent of targeted therapies, such as sorafenib and lenvatinib, has transformed treatment protocols, offering new hope for patients. However, challenges persist, including the high cost of innovative treatments and limited access to care in low-resource settings, which can hinder market growth. Furthermore, the lack of early diagnostic tools often results in late-stage diagnosis, complicating treatment options. Nevertheless, opportunities abound in research for novel therapies, particularly immunotherapy and combination treatments, as well as initiatives aimed at increasing awareness and screening, which could lead to earlier diagnosis and better patient outcomes in the liver cancer landscape.

Liver Cancer Drug Market- Market Dynamics

Rising Incidences of Liver Cancer Drive Growth in the Liver Cancer Drug Market

The rising incidences of liver cancer are significantly driving growth in the Liver Cancer Drug Market, as reported by the World Health Organization, which indicates that liver cancer cases have increased by over 75% in the past two decades. This alarming trend is primarily attributed to rising rates of hepatitis B and C infections, excessive alcohol consumption, and obesity, with the American Cancer Society estimating that in 2023, approximately 43,000 new cases of liver cancer will be diagnosed in the U.S. alone. As awareness grows regarding the importance of early detection and treatment, pharmaceutical companies are responding by developing innovative therapies. For instance, recent advancements in targeted therapies, such as immune checkpoint inhibitors, have shown promise in improving survival rates for patients with advanced liver cancer. Additionally, organizations like the American Association for the Study of Liver Diseases are promoting research and clinical trials to enhance treatment options and better understand the disease, thereby addressing the urgent need for effective therapies in this rapidly evolving market.

Liver Cancer Drug Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 17.82% over the forecast period (2024-2032)

Based on Drug Class segmentation, VEGF Inhibitors were predicted to show maximum market share in the year 2023

Based on Therapy Type segmentation, Targeted Therapy was the leading type in 2023

Based on Route of Administration segmentation, Oral was the leading type in 2023

On the basis of region, North America was the leading revenue generator in 2023

Liver Cancer Drug Market- Segmentation Analysis:

The Global Liver Cancer Drug Market is segmented on the basis of Drug Class, Therapy Type, Route of Administration, End-User, and Region.

The market is divided into four categories based on Drug Class: VEGF Inhibitors, PD-1/PD-L1 Inhibitors, Tyrosine Kinase Inhibitors, and Immune Checkpoint Inhibitors. VEGF inhibitors rank highest in the Liver Cancer Drug Market due to their established efficacy in treating hepatocellular carcinoma. PD-1/PD-L1 inhibitors follow, offering promising immunotherapeutic options. Tyrosine kinase inhibitors (TKIs) are next, while immune checkpoint inhibitors are gaining traction for advanced cases.

The market is divided into four categories based on Therapy Type: Chemotherapy, Targeted Therapy, Immunotherapy, and Combination Therapy. Targeted therapy leads the Liver Cancer Drug Market due to its effectiveness and precision in treatment. Immunotherapy follows closely, providing innovative options for advanced liver cancer. Combination therapy ranks next, while chemotherapy remains a traditional approach with limited efficacy in advanced stages.

Liver Cancer Drug Market- Geographical Insights

North America dominates the Liver Cancer Drug Market, driven by advanced healthcare infrastructure and a high prevalence of liver cancer, particularly in the United States. In 2022, the U.S. Food and Drug Administration (FDA) approved a new combination therapy involving lenvatinib and pembrolizumab, marking a significant advancement in treatment options for patients with advanced hepatocellular carcinoma (HCC). Additionally, the American Cancer Society reported that liver cancer incidence rates have been rising steadily, prompting increased funding for research initiatives aimed at better diagnostic tools and therapeutic options. In Europe, countries like Germany and France are witnessing a surge in clinical trials focusing on innovative drug combinations, reflecting a commitment to enhancing patient care. Asia-Pacific is emerging as a key region, with significant investments in liver cancer research due to the high prevalence of hepatitis-related liver cancer. Collaborations, such as the partnership between pharmaceutical companies and research institutions in Japan, aim to expedite the development of new therapies, highlighting a global effort to combat liver cancer effectively.

Liver Cancer Drug Market- Competitive Landscape:

The competitive landscape of the Liver Cancer Drug Market is predominantly led by North America, where major pharmaceutical companies like Bayer, Bristol-Myers Squibb, and Merck are actively advancing their portfolios. In 2023, Bayer announced the launch of a new formulation of sorafenib, aimed at improving patient adherence and outcomes in hepatocellular carcinoma (HCC) treatment. Meanwhile, Bristol-Myers Squibb's collaboration with the National Cancer Institute has accelerated the development of novel immunotherapies, significantly enhancing treatment options available to patients. In recent news, Merck's acquisition of a biotechnology firm specializing in liver cancer research has fortified its position in the market, allowing for an expanded pipeline of innovative therapies. Additionally, the European market is witnessing increased activity, with clinical trials underway for combination therapies that incorporate existing drugs with emerging agents, reflecting a growing trend towards personalized medicine. These developments highlight a dynamic competitive environment where collaboration, innovation, and strategic partnerships are essential for advancing treatment options and improving patient outcomes in the liver cancer landscape.

Recent Developments:

In August 2024, Bristol Myers Squibb's supplemental biologics license application for the first-line treatment of unresectable hepatocellular carcinoma was accepted by the FDA. This marks a significant step in advancing treatment options for patients with this type of liver cancer.

In February 2024, The FDA granted fast-track designation to BST02, a T-cell therapy for all liver cancer types, including hepatocellular carcinoma and cholangiocarcinoma. This innovative treatment utilizes tumor-infiltrating lymphocytes and is set for evaluation in a phase 1/2 clinical trial.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL LIVER CANCER DRUG MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

GLOBAL LIVER CANCER DRUG MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032

GLOBAL LIVER CANCER DRUG MARKET, BY THERAPY TYPE- MARKET ANALYSIS, 2019 - 2032

GLOBAL LIVER CANCER DRUG MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

GLOBAL LIVER CANCER DRUG MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

GLOBAL LIVER CANCER DRUG MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

Table of Contents

1. Liver Cancer Drug Market Overview

2. Executive Summary

3. Liver Cancer Drug Key Market Trends

4. Liver Cancer Drug Industry Study

5. Liver Cancer Drug Market: COVID-19 Impact Analysis

6. Liver Cancer Drug Market Landscape

7. Liver Cancer Drug Market - By Drug Class

8. Liver Cancer Drug Market - By Therapy Type

9. Liver Cancer Drug Market - By Route of Administration

10. Liver Cancer Drug Market - By End-User

11. Liver Cancer Drug Market- By Geography

12. Key Vendor Analysis- Liver Cancer Drug Industry

13. 360 Degree Analyst View

14. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â